Compound profile
Also known as: LY3298176 · dual GIP/GLP-1 agonist · Mounjaro · Zepbound
A dual GIP/GLP-1 receptor agonist (marketed as Mounjaro and Zepbound) with extensive clinical data in type 2 diabetes and obesity. Frequently compared head-to-head with semaglutide in conversations about metabolic peptides and body recomposition.
Tirzepatide is a synthetic peptide that activates two hormone receptors at once, GIP and GLP-1, both part of the body's incretin system that regulates insulin and appetite after eating. Eli Lilly developed it as a single-chain peptide, and it carries a long fatty acid chain attached through a linker that lets it bind to albumin in the blood, which is what allows once-weekly dosing instead of the daily injections older diabetes peptides required.
Unlike most compounds discussed on this site, tirzepatide is not a research chemical. It is an FDA-approved prescription medicine, sold as Mounjaro for type 2 diabetes since 2022 and as Zepbound for chronic weight management since 2023, and it carries one of the largest clinical trial programs of any peptide in this class, spanning the SURPASS trials in diabetes and the SURMOUNT trials in obesity.
It is frequently compared head-to-head with semaglutide, the GLP-1-only peptide that popularized this drug category, because trials have directly pitted the two against each other. The dual-receptor mechanism is the main thing that distinguishes it, and it shows up in conversations about metabolic health and body composition alongside less-studied research peptides even though its evidence base and regulatory status are entirely different.
Simultaneously engages GIP and GLP-1 receptors, influencing insulin secretion, appetite, and gastric emptying. Dual agonism is thought to contribute to stronger metabolic effects than GLP-1 alone in some trials.
Tirzepatide works by binding to and activating two separate receptors, GIP and GLP-1, that the body normally engages through hormones released from the gut after eating. Through the GLP-1 receptor, it stimulates glucose-dependent insulin release (meaning it ramps up insulin mainly when blood sugar is high, not constantly), suppresses glucagon, slows gastric emptying so food is digested more gradually, and acts on appetite centers in the brain to increase feelings of fullness.
The GIP receptor activity is what sets it apart from single-target GLP-1 drugs like semaglutide. GIP has its own effects on insulin secretion and on fat tissue, and researchers believe engaging both receptors together produces a stronger combined effect on blood sugar and body weight than hitting GLP-1 alone, though the exact division of labor between the two receptors is still an active research question. The long fatty acid chain attached to the peptide backbone slows its clearance from the body, which is why once-weekly injections are enough to maintain a steady effect.
Large randomized trials show meaningful HbA1c and weight reductions. Evidence quality is among the strongest in the metabolic peptide class commonly discussed online.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
The SURMOUNT-1 trial reported substantial body weight loss compared with placebo in adults with obesity or overweight, at the higher end of what incretin-based peptides have shown.
The SURPASS trial program reported meaningful HbA1c reductions in type 2 diabetes, with the head-to-head SURPASS-2 trial reporting greater glycemic and weight outcomes than semaglutide.
Post hoc analyses of SURMOUNT-1 report improvements in blood pressure, triglycerides, LDL cholesterol, and HDL cholesterol alongside weight loss.
Data from SURPASS-4 and the SURPASS-CVOT program report slower kidney function (eGFR) decline in people with chronic kidney disease, and the SUMMIT trial reported fewer heart failure events in people with obesity and heart failure with preserved ejection fraction.
Prescription product with labeled indications; not a research peptide for DIY use. GI adverse events, gallbladder risk signals, and muscle-loss concerns during rapid weight loss deserve diligence. Contraindications and monitoring matter.
Gastrointestinal side effects, nausea, diarrhea, vomiting, and constipation, are the most common issue, especially during dose escalation, and trials report they generally ease over time as the body adjusts. Serious but less common risks include gallbladder disease and, rarely, pancreatitis, both plausibly connected to how quickly the drug can produce weight loss. Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors, seen in rodent studies, and it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Muscle and lean mass loss during rapid weight reduction is an active area of research rather than a settled finding. Compounded, non-FDA-approved versions of tirzepatide have generated their own separate safety reports to the FDA, tied to inconsistent manufacturing rather than the approved product itself. Because this is a prescription medicine, not a DIY research compound, its use requires medical evaluation and monitoring rather than self-directed experimentation.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Semaglutide, tirzepatide, and retatrutide are commonly compared when people research metabolic and fat-loss peptide classes, from approved GLP-1/GIP medicines to investigational triple agonists.
These are distinct molecules with different approval statuses and trial populations. Comparison talk is educational, not a recommendation to obtain or combine them.
Fat loss · Metabolic
